Strategy
MSTR
Tesla
TSLA
MARA Holdings
MARA
4
Meta Platforms
META
5
Salesforce
CRM
US Stock MarketDetailed Quotes
SNDX Syndax Pharmaceuticals
- 13.700
- +0.280+2.09%
Close Apr 29 16:00 ET
- 13.450
- -0.250-1.82%
Pre 08:24 ET
1.18BMarket Cap-3.68P/E (TTM)
13.980High13.250Low1.66MVolume13.450Open13.420Pre Close22.69MTurnover2.16%Turnover RatioLossP/E (Static)86.04MShares25.07052wk High4.09P/B1.05BFloat Cap9.66052wk Low--Dividend TTM76.96MShs Float29.860Historical High--Div YieldTTM5.44%Amplitude3.390Historical Low13.674Avg Price1Lot Size
About Syndax Pharmaceuticals Company
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.
Company Profile
SymbolSNDX
Company NameSyndax Pharmaceuticals
Listing DateMar 3, 2016
Issue Price12.00
Founded2005
CEOMr. Michael A. Metzger
MarketNASDAQ
Employees270
Fiscal Year Ends12-31
Address730 Third Avenue,floor 9
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10017
Phone1-781-419-1400
Websitehttp://www.syndax.com
Company Executives
- Name
- Position
- Salary
- Michael A. Metzger
- Director and Chief Executive Officer
- 7.71M
- Steven Closter
- Chief Commercial Officer
- 3.56M
- Keith A. Goldan
- Chief Financial Officer and Principal Accounting Officer
- 2.82M
- Dennis G. Podlesak
- Chairman of the Board
- 954.42K
- Dr. Neil Gallagher, M.D.
- President and Head of Research and Development
- 2.93M
- Jennifer Ann Jarrett
- Independent Director
- 438.67K
- William Meury
- Independent Director
- 424.40K
- Pierre Legault, C.P.A.,M.B.A.
- Independent Director
- 501.49K
- Keith A. Katkin
- Independent Director
- 507.19K
- Dr. Martin H. Huber, M.D.
- Independent Director
- 441.52K
- Dr. Aleksandra Rizo, M.D.,PhD
- Independent Director
- 534.26K
- Luke J. Albrecht
- General Counsel and Secretary
- 2.47M
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀